Experimental analysis reveals drug combinations improve outcomes in CDKN2A/MTAP co-deleted cancer, suggesting promising treatment avenues.
Figure S10. Colony formation assays of three cell lines harboring CDKN2A/MTAP co-deletions and KRAS G12C mutations treated with KRAS G12C inhibitor adagrasib, PRMT5 inhibitor MRTX1719, or the combination across all drug concentrations.
No takes yet. Share an insight, caveat, or question.
Knoll et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: